Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication

Acta Haematol. 2020;143(1):65-68. doi: 10.1159/000500975. Epub 2019 Jul 10.

Abstract

Midostaurin is a tyrosine multikinase inhibitor approved for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with mutated Fms-like tyrosine kinase-3. We describe a case report of a 49-year-old AML patient treated with an intensive chemotherapy regimen followed by midostaurin. After achieving complete remission with blood count recovery, he suffered from a serious, rare complication of necrotizing hemorrhagic gastritis with no evidence of infection or malignant infiltration, possibly associated with midostaurin therapy.

Keywords: Acute myeloid leukemia; Hemorrhagic gastritis; Midostaurin.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Pain / etiology
  • Gastritis / etiology*
  • Gastritis / pathology
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Remission Induction
  • Staurosporine / adverse effects
  • Staurosporine / analogs & derivatives*
  • Staurosporine / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • Protein Kinase Inhibitors
  • Staurosporine
  • midostaurin